Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive, or FISH-negative early-stage breast cancer patients for HER2 status

被引：1
|
作者：
Garrison, L. P.
Lalla, D.
Brammer, M. G.
Wang, B.
Babigumira, J.
Perez, E. A.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] Mayo Clin, Jacksonville, FL 32224 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.6133
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6133
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer
    Kurian, Allison W.
    Newton Thompson, Rebecca
    Gaw, Allison F.
    Arai, Sally
    Ortiz, Rafael
    Garber, Alan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (06) : 634 - 641
  • [22] Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer
    Fagnani, Francis
    Colin, Xavier
    Arveux, Patrick
    Coudert, Bruno
    Misset, Jean-Louis
    BULLETIN DU CANCER, 2007, 94 (7-8) : 711 - 720
  • [23] ASO Author Reflections: Beyond the Binary: Using IHC Status to Predict Response to Neoadjuvant Therapy in HER2+ Early-Stage Breast Cancer
    Leah K. Winer
    Austin D. Williams
    Annals of Surgical Oncology, 2025, 32 (2) : 967 - 968
  • [24] COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER
    Nguyen, T. T. T.
    Yagudina, R.
    Kulikov, A. U.
    VALUE IN HEALTH, 2011, 14 (03) : A165 - A165
  • [25] Frequency of dose reductions of abemaciclib in metastatic and early-stage hormone positive, HER2 negative breast cancer.
    Ter-Zakarian, Anna
    Donovan, Lauren N.
    Nasraty, Farah
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] A COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB REGIMENS IN EARLY HER2/NEU-POSITIVE BREAST CANCER IN COLOMBIA
    Buendia Rodriguez, J. A.
    Vallejos, C.
    VALUE IN HEALTH, 2011, 14 (07) : A449 - A449
  • [27] Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt
    Elsisi, Gihan Hamdy
    Nada, Yousery
    Rashad, Noha
    Carapinha, Joao
    Noor, Ahmad O.
    Almasri, Diena M.
    Al Zaidy, Mostafa
    Foad, Ahmed
    Khaled, Hussien
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (06) : 575 - 580
  • [28] Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer
    Lidgren, M.
    Joensson, B.
    Rehnberg, C.
    Willking, N.
    Bergh, J.
    ANNALS OF ONCOLOGY, 2008, 19 (03) : 487 - 495
  • [29] The immunomodulatory impacts of endocrine therapy on host immunity in early-stage hormone receptor positive, HER2 negative breast cancer
    Sammons, Sarah L.
    Dent, Susan Faye
    Chang, Ching-Yi
    Liu, Siyao
    Chan, Isaac
    Weinhold, Kent J.
    Perou, Charles M.
    McDonnell, Donald P.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer
    Jesse A. Sussell
    Joshua A. Roth
    Craig S. Meyer
    Anita Fung
    Svenn A. Hansen
    Advances in Therapy, 2022, 39 : 1375 - 1392
12345